Alkermes (ALKS) Long-Term Debt Issuances (2013 - 2026)

Alkermes (ALKS) reported Long-Term Debt Issuances of $1.5 billion for Q1 2026, up 6313.87% quarter-over-quarter from $23.6 million in Q1 2021.

Alkermes (ALKS) Long-Term Debt Issuances (2013 - 2026) Analysis & Trends

Alkermes (ALKS) has 3 years of Long-Term Debt Issuances data on file, last reported at $1.5 billion in Q1 2026.

Long-Term Debt Issuances for Q1 2026 came in at $1.5 billion, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $1.5 billion (changed N/A YoY), and the FY2021 annual result was $23.6 million, changed N/A from the prior year.
Long-Term Debt Issuances improved to $1.5 billion in Q1 2026 per ALKS's latest filing, from $23.6 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $1.5 billion in Q1 2026 and troughed at $1.5 billion in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	LT Debt Issuance (Qtr)
1	Teva Pharmaceutical Industries	38.34 Bn	34.60 Bn	1.97 Bn	-
2	Zoetis	33.27 Bn	31.33 Bn	1.62 Bn	-
3	United Therapeutics	23.75 Bn	21.60 Bn	648.10 Mn	-
4	Aurora Cannabis	17.11 Bn	17.03 Bn	33.43 Mn	-
5	Neurocrine Biosciences	16.37 Bn	15.05 Bn	800.70 Mn	-
6	Elanco Animal Health	11.78 Bn	11.35 Bn	785.00 Mn	-
7	Alkermes	7.05 Bn	6.54 Bn	-116.06 Mn	1.51 Bn
8	Lantheus Holdings	6.49 Bn	5.99 Bn	230.92 Mn	-
9	Hims & Hers Health	6.19 Bn	5.44 Bn	396.79 Mn	-
10	Liquidia	5.63 Bn	5.40 Bn	121.79 Mn	-

Download Data